Natasha Rekhtman

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Clinicogenomic analysis of <i>EGFR</i> -mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation

  Science Translational Medicine · 2026-06-17

• Supplementary Table S1 from Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas

  2025-11-03

• Data from Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas

  2025-11-03

• Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms

  JCO Precision Oncology · 2025-11-01 · 1 citations

• 2MO Integrated histopathologic modeling of detailed tumor subtypes and actionable biomarkers

  ESMO Real World Data and Digital Oncology · 2025-11-01

• P2.06.12 TP53/RB1-Mutant Squamous Cell Lung Cancers: Clinicopathologic Features and Outcomes

  Journal of Thoracic Oncology · 2025-10-01

• Interpathologist Diagnostic Agreement for Non–Small Cell Lung Carcinomas Using Current and Recent Classifications

  UNC Libraries · 2025-10-01

• OA13.04 Highly Proliferative (G3) Lung Carcinoids: IASLC Pathology Committee Study With Proposal for Inclusion in WHO Classification

  Journal of Thoracic Oncology · 2025-10-01

• Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas

  Clinical Cancer Research · 2025-09-05 · 7 citations

• Machine Learning Using &gt;300,000 H&amp;E Images Refines Cancer of Unknown Primary Subtyping

  International Journal of Radiation Oncology*Biology*Physics · 2025-09-01

• Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas

  JCO Precision Oncology · 2025-09-01

• Delta-like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasmsPreprint

  medRxiv · 2025-06-25 · 2 citations

• Supplementary Figures S1-S10 from Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted TherapyPreprint

  2025-06-03

• Data from Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted TherapyPreprint

  2025-06-03

• Supplementary Tables S1-S8 from Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy

  2025-06-03

• Landscape of functional DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs).

  Journal of Clinical Oncology · 2025-05-28 · 1 citations

• Responsiveness of different MET tumour alterations to type I and type II MET inhibitors

  Clinical and Translational Medicine · 2025-05-01 · 2 citations

• 337 Cytomorphology of Pulmonary Large Cell Neuroendocrine Carcinoma (LCNEC): A Comparative Analysis between Fine Needle Aspiration (FNA) Cytologic Preparations

  Laboratory Investigation · 2025-03-01

• 1346 Harnessing GPT-Driven AI for Enhanced Pathology: Development and Applications of the 'Pathology 2nd Brain'

  Laboratory Investigation · 2025-03-01

• 1707 Analysis of TRPS1 and SOX10 Expression in 216 Non-small Cell Lung Carcinomas

  Laboratory Investigation · 2025-03-01